{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"GILD","limit":50},"count":50,"signals":[{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"no earlier than age 50 and no later than age 75, or on the date of his or her cessation of Board service or on the second or fifth anniversary of that cessation date, in a lump sum or in annual installments over a period not to exceed 10 years. An early distribution is permitted in the event of a financial hardship. In the event of the non-employee directors death, an account balance will be distrib","filed_date":"2026-03-20","accession":"0001308179-26-000106","full_text":"https://origin.rootz.global/static/filing/0001308179-26-000106.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":18,"context":"d with our information systems and technology (including cybersecurity). |  |  Oversees risks related to our compensation practices to confirm that these practices are not reasonably likely to have a material adverse effect on Gilead or encourage employees to take unnecessary or excessive risks; also oversees risks related to talent management and succession planning of our executive officers, as well as strategies and","filed_date":"2026-03-20","accession":"0001308179-26-000106","full_text":"https://origin.rootz.global/static/filing/0001308179-26-000106.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":107,"context":"agreements were signed in advance of any global regulatory submissions to enable these countries to quickly introduce generic versions of lenacapavir for HIV prevention, if approved. In July 2025, we announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis. Through the agreement, we will supply","filed_date":"2026-03-20","accession":"0001308179-26-000106","full_text":"https://origin.rootz.global/static/filing/0001308179-26-000106.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":100,"context":"we may be required to pay state Medicaid agencies and discounts provided to covered entities under 340B. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, changes to the calculation of rebates under the Medicaid program could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B-cove","filed_date":"2026-02-24","accession":"0000882095-26-000006","full_text":"https://origin.rootz.global/static/filing/0000882095-26-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":42,"context":"lization, Etc |  13 | | |  Section 3.04. |  Authority; Binding Nature of Agreement |  15 | | |  Section 3.05. |  SEC Filings; Financial Statements |  16 | | |  Section 3.06. |  Absence of Changes; No Material Adverse Effect |  18 | | |  Section 3.07. |  Title to Assets |  18 | | |  Section 3.08. |  Real Property |  18 | | |  Section 3.09. |  Intellectual Property |  19 | | |  Section 3.10. |  Data Privacy |  21 | | |  S","filed_date":"2026-02-23","accession":"0001104659-26-018314","full_text":"https://origin.rootz.global/static/filing/0001104659-26-018314.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":25,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2025-11-07","accession":"0000882095-25-000047","full_text":"https://origin.rootz.global/static/filing/0000882095-25-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":26,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2025-08-07","accession":"0000882095-25-000032","full_text":"https://origin.rootz.global/static/filing/0000882095-25-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":26,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2025-05-07","accession":"0000882095-25-000012","full_text":"https://origin.rootz.global/static/filing/0000882095-25-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"d with our information systems and technology (including cybersecurity). |  |  Oversees risks related to our compensation practices to confirm that these practices are not reasonably likely to have a material adverse effect on Gilead or encourage employees to take unnecessary or excessive risks; also oversees risks related to talent management and succession planning of our executive officers. |  |  Oversees risks relat","filed_date":"2025-03-27","accession":"0001308179-25-000252","full_text":"https://origin.rootz.global/static/filing/0001308179-25-000252.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":104,"context":"C), a rare liver disease that primarily affects women. Initial demand in the U.S. exceeded our expectations, and we look forward to reaching more patients this year. On the pipeline side, we recently entered into a strategic partnership with LEO Pharma to accelerate the development and commercialization of an oral STAT6 program for the potential treatment of patients with inflammatory diseases. Importantly, all these advancements ac","filed_date":"2025-03-27","accession":"0001308179-25-000252","full_text":"https://origin.rootz.global/static/filing/0001308179-25-000252.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":94,"context":"we may be required to pay state Medicaid agencies and discounts provided to covered entities under 340B. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, the continued growth of the 340B program limits the prices we may charge on an increasing percentage of sales. Changes to the calculation of rebates under the Medicaid p","filed_date":"2025-02-28","accession":"0000882095-25-000006","full_text":"https://origin.rootz.global/static/filing/0000882095-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":26,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2024-11-12","accession":"0000882095-24-000028","full_text":"https://origin.rootz.global/static/filing/0000882095-24-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":26,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2024-08-08","accession":"0000882095-24-000022","full_text":"https://origin.rootz.global/static/filing/0000882095-24-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":26,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2024-05-08","accession":"0000882095-24-000013","full_text":"https://origin.rootz.global/static/filing/0000882095-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ed with our information systems and technology (including cybersecurity). |  |  Oversees risks related to our compensation practices to ensure that these practices are not reasonably likely to have a material adverse effect on Gilead or encourage employees to take unnecessary or excessive risks; also oversees risks related to talent management and succession planning of our executive officers. |  |  Oversees risks relat","filed_date":"2024-03-28","accession":"0001308179-24-000348","full_text":"https://origin.rootz.global/static/filing/0001308179-24-000348.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":111,"context":"of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. |  |  FOR | | |  3 |  To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. |  |  FOR | | |  4 |  To approve an amendment to our Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.","filed_date":"2024-03-28","accession":"0001308179-24-000348","full_text":"https://origin.rootz.global/static/filing/0001308179-24-000348.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":94,"context":"s and discounts provided to covered entities under Section 340B of the Public Health Service Act (340B). Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, the continued growth of the 340B program limits the prices we may charge on an increasing percentage of sales. Changes to the calculation of rebates under the Medicaid p","filed_date":"2024-02-23","accession":"0000882095-24-000007","full_text":"https://origin.rootz.global/static/filing/0000882095-24-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":23,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2023-11-07","accession":"0000882095-23-000031","full_text":"https://origin.rootz.global/static/filing/0000882095-23-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":20,"context":"ization and is in good standing under the laws of each jurisdiction which requires such qualification, except, in each case, where the failure so to qualify or to be in good standing would not have a Material Adverse Effect (as defined below). The Significant Subsidiaries are the only significant subsidiaries (as defined in Rule1-02 of Regulation S-X under the Exchange Act) of the Company. As used herein, **Material Adv","filed_date":"2023-09-14","accession":"0001104659-23-100638","full_text":"https://origin.rootz.global/static/filing/0001104659-23-100638.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":23,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2023-08-04","accession":"0000882095-23-000025","full_text":"https://origin.rootz.global/static/filing/0000882095-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":23,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2023-05-03","accession":"0000882095-23-000017","full_text":"https://origin.rootz.global/static/filing/0000882095-23-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"no earlier than age 50 and no later than age 75, or on the date of his or her cessation of Board service or on the second or fifth anniversary of that cessation date, in a lump sum or in annual installments not to exceed 10 years. An early distribution is permitted in the event of a financial hardship. In the event of death, an account balance will be distributed in a lump sum to the directors desig","filed_date":"2023-03-23","accession":"0001308179-23-000323","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"d technology (including cybersecurity). |  |  COMPENSATION AND TALENT COMMITTEE Oversees risks related to our compensation practices to ensure that these practices are not reasonably likely to have a material adverse effect on Gilead or encourage employees to take unnecessary or excessive risks; also oversees risks related to talent management and succession planning of our executive officers. |  |  NOMINATING AND CORPO","filed_date":"2023-03-23","accession":"0001308179-23-000323","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":94,"context":"of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. |  |  FOR | | |  3 |  To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. |  |  FOR | | |  4 |  To approve, on an advisory basis, the frequency of future advisory stockholder votes on executive compensation. |  |  1 YEAR | | |  5 |  To","filed_date":"2023-03-23","accession":"0001308179-23-000323","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":26,"context":"s and discounts provided to covered entities under Section 340B of the Public Health Service Act (340B). Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, the continued growth of the 340B program limits the prices we may charge on an increasing percentage of sales. Changes to the calculation of rebates under the Medicaid p","filed_date":"2023-02-22","accession":"0000882095-23-000007","full_text":"https://origin.rootz.global/static/filing/0000882095-23-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":24,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2022-11-02","accession":"0000882095-22-000027","full_text":"https://origin.rootz.global/static/filing/0000882095-22-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":23,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2022-08-08","accession":"0000882095-22-000019","full_text":"https://origin.rootz.global/static/filing/0000882095-22-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":25,"context":"application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2022-05-04","accession":"0000882095-22-000013","full_text":"https://origin.rootz.global/static/filing/0000882095-22-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"d technology (including cybersecurity). |  |  COMPENSATION AND TALENT COMMITTEE Oversees risks related to our compensation practices to ensure that these practices are not reasonably likely to have a material adverse effect on Gilead or encourage employees to take unnecessary or excessive risks; also oversees risks related to talent management and succession planning of our executive officers. |  |  NOMINATING AND CORPO","filed_date":"2022-03-24","accession":"0001206774-22-000832","full_text":"https://origin.rootz.global/static/filing/0001206774-22-000832.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":99,"context":"Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. |  FOR | | |  Proposal 3 To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. |  FOR | | |  Proposal 4 To approve the Gilead Sciences, Inc. 2022 Equity Incentive Plan. |  FOR | | |  Proposal 5 To vote on a stockholder proposal, if properly","filed_date":"2022-03-24","accession":"0001206774-22-000832","full_text":"https://origin.rootz.global/static/filing/0001206774-22-000832.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":27,"context":"that we may be required to pay state Medicaid agencies and discounts provided to 340B covered entities. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, in December 2020, Centers for Medicare & Medicaid Services (CMS) issued a final rule that will make certain changes to the calculation of rebates under the Medicaid Drug","filed_date":"2022-02-23","accession":"0000882095-22-000007","full_text":"https://origin.rootz.global/static/filing/0000882095-22-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":10,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2021-11-03","accession":"0000882095-21-000029","full_text":"https://origin.rootz.global/static/filing/0000882095-21-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":10,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2021-08-05","accession":"0000882095-21-000021","full_text":"https://origin.rootz.global/static/filing/0000882095-21-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":7,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2021-05-06","accession":"0000882095-21-000013","full_text":"https://origin.rootz.global/static/filing/0000882095-21-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":94,"context":"the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2021. | | |  Proposal 3 |  |  FOR | | |  To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. | | |  Proposal 4 |  |  AGAINST | | |  To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the","filed_date":"2021-03-30","accession":"0001206774-21-000908","full_text":"https://origin.rootz.global/static/filing/0001206774-21-000908.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":9,"context":"that we may be required to pay state Medicaid agencies and discounts provided to 340B covered entities. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, in December 2020, CMS issued a final rule that will make certain changes to the calculation of rebates under the Medicaid Drug Rebate Program. Among other changes, effec","filed_date":"2021-02-25","accession":"0000882095-21-000008","full_text":"https://origin.rootz.global/static/filing/0000882095-21-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":5,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2020-11-04","accession":"0000882095-20-000027","full_text":"https://origin.rootz.global/static/filing/0000882095-20-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":21,"context":"ization and is in good standing under the laws of each jurisdiction which requires such qualification, except, in each case, where the failure so to qualify or to be in good standing would not have a Material Adverse Effect (as defined below). Each of Gilead Biopharmaceutics Ireland UC, an unlimited company organized under the laws of the Republic of Ireland (**Gilead Biopharmaceutics**), Gilead Sciences Ireland UC, an","filed_date":"2020-09-29","accession":"0001104659-20-109844","full_text":"https://origin.rootz.global/static/filing/0001104659-20-109844.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2020-08-06","accession":"0000882095-20-000019","full_text":"https://origin.rootz.global/static/filing/0000882095-20-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2020-05-06","accession":"0000882095-20-000013","full_text":"https://origin.rootz.global/static/filing/0000882095-20-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"no earlier than age 50 and no later than age 75, or on the date of his or her cessation of Board service or on the second or fifth anniversary of that cessation date, in a lump sum or in annual installments not to exceed 10 years. An early distribution is permitted in the event of a financial hardship. In the event of death, an account balance will be distributed in a lump sum to the directors desig","filed_date":"2020-03-24","accession":"0001206774-20-000886","full_text":"https://origin.rootz.global/static/filing/0001206774-20-000886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":122,"context":"pendent registered public accounting firm of Gilead for the fiscal year ending December 31, 2020. |  | | |  |  Proposal 3 |  |  FOR | | |  |  To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. |  | | |  |  Proposal 4 |  |  AGAINST | | |  |  To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy","filed_date":"2020-03-24","accession":"0001206774-20-000886","full_text":"https://origin.rootz.global/static/filing/0001206774-20-000886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":17,"context":"dates or products; or whether any products, once launched, will be commercially successful.Failure to launch commercially successful new products or new indications for existing products could have a material adverse effect on our future revenues, results of operations and long-term success. 13 Our inability to accurately predict demand for our products and fluctuations in purchasing patterns or wholesaler inventories m","filed_date":"2020-02-25","accession":"0000882095-20-000006","full_text":"https://origin.rootz.global/static/filing/0000882095-20-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2019-11-05","accession":"0000882095-19-000027","full_text":"https://origin.rootz.global/static/filing/0000882095-19-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":10,"context":"t to permanent injunctive relief. Other Matters We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations. 23 | | | | | 12. | STOCKHOLDERS EQUITY | | Stock Repurchase Program In the first quarter of 2016, our Board of Directors aut","filed_date":"2019-08-06","accession":"0000882095-19-000020","full_text":"https://origin.rootz.global/static/filing/0000882095-19-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2019-05-08","accession":"0000882095-19-000014","full_text":"https://origin.rootz.global/static/filing/0000882095-19-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"no earlier than age 50 and no later than age 75, or on the date of his or her cessation of Board service or on the second or fifth anniversary of that cessation date, in a lump sum or in annual installments not to exceed 10 years. An early distribution is permitted in the event of a financial hardship. In the event of death, an account balance will be distributed in a lump sum to the directors desig","filed_date":"2019-03-25","accession":"0001206774-19-001013","full_text":"https://origin.rootz.global/static/filing/0001206774-19-001013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":112,"context":"patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy. | | |  |  R&D Investments: | | |  |  We invested $5 billion in R&D for the year and continued to advance our pipeline with 41 Phase 3 clinical trials at year-end. | | |  |  In addition, our financial strength allows us to advance and expand our R&D pipeline t","filed_date":"2019-03-25","accession":"0001206774-19-001013","full_text":"https://origin.rootz.global/static/filing/0001206774-19-001013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"re viability and destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material. Efforts to control prescription drug prices could also have a material adverse effect on our business. For example, in 2018, President Trump and the Secretary of the U.S. Department of Health and Human Services (HHS) released the \"American Patients First Blueprint\" and have begun impl","filed_date":"2019-02-26","accession":"0000882095-19-000006","full_text":"https://origin.rootz.global/static/filing/0000882095-19-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GILD","company":"GILEAD SCIENCES, INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":9,"context":"ication (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded products ap","filed_date":"2018-11-06","accession":"0000882095-18-000029","full_text":"https://origin.rootz.global/static/filing/0000882095-18-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"bd038b49cd5e71492e821ce5041ec6c7f965981ba3a82d788c4d441742be706d","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a6ec4a21c284d6b4fe39fdf7deebed04c2059c1d72f36c8e81e7e731dc84a789","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":4,"hourly_limit":500,"remaining":496,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}